Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High Following Analyst Upgrade

Key Points

• Supernus Pharmaceuticals reached a new 52-week high after Cantor Fitzgerald raised its price target from $42.00 to $46.00, maintaining an overweight rating on the stock.
• Institutional investors have shown increased interest, with Armistice Capital raising its position by 7.4% and BNP Paribas Financial Markets increasing holdings by 248% in the fourth quarter.
• The stock has reported a 14.2% increase recently, with a market capitalization of $2.40 billion and a price-to-earnings ratio of 38.60.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report)'s share price hit a new 52-week high during trading on Wednesday after Cantor Fitzgerald raised their price target on the stock from $42.00 to $46.00. Cantor Fitzgerald currently has an overweight rating on the stock. Supernus Pharmaceuticals traded as high as $41.51 and last traded at $42.29, with a volume of 624173 shares. The stock had previously closed at $37.53.

Separately, Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several large investors have recently made changes to their positions in SUPN. Armistice Capital LLC boosted its holdings in shares of Supernus Pharmaceuticals by 7.4% in the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock worth $170,169,000 after buying an additional 360,000 shares during the last quarter. Woodline Partners LP boosted its stake in Supernus Pharmaceuticals by 124.8% in the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock valued at $15,326,000 after acquiring an additional 235,257 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Supernus Pharmaceuticals by 248.0% in the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock valued at $10,581,000 after acquiring an additional 208,552 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at approximately $6,847,000. Finally, GW&K Investment Management LLC grew its position in shares of Supernus Pharmaceuticals by 14.6% during the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after acquiring an additional 176,091 shares during the period.

Supernus Pharmaceuticals Stock Performance

The company has a market cap of $2.31 billion, a PE ratio of 35.80 and a beta of 0.74. The company's 50 day moving average price is $33.24 and its 200-day moving average price is $33.45.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.